NCT03463681View on ClinicalTrials.gov

A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

April 8, 2021

Study Completion Date

April 8, 2021

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Cabometyx

cabozantinib 60 mg orally once daily

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT03463681 - A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma | Biotech Hunter | Biotech Hunter